Proactive Investors - Run By Investors For Investors

NetScientific says portfolio company Wanda granted two new US patents significantly extending protection for core technology

Netscientific said the patents will significantly extend protection for the core technology used in Wanda's software application for remote health and patient management
Patents
It added that the patents are the result of research on clinical time-series data at UCLA

NetScientific PLC (LON:NSCI) has announced the issue by the US Patent and Trademark Office of two new patents exclusively licensed to its portfolio company, Wanda.

The transatlantic healthcare IP commercialisation group said the patents will significantly extend protection for the core technology used in Wanda's software application for remote health and patient management.

READ: Netscientific associate Vortex Biosciences makes first commercial sale

It added that the patents - titled, "Apparatus, System, and Method for Detecting Activities and Anomalies in Time Series Data" and "Efficient Searching of Stationary Datasets" - are the result of research on clinical time-series data at UCLA.

Commenting on the news, Francois R. Martelet, NetScientific's chief executive officer and Wanda’s chairman said: "We are delighted to announce that Wanda is further strengthening its IP, an important step in its continued corporate development.

READ: NetScientific’s Glycotest subsidiary allowed Chinese patent for liver cancer blood test

“We believe Wanda's class-leading predictive and behavioural analytics platform acts as a competitive differentiator in the emerging and highly exciting Digital Health sector."

View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use